drugset / Trial / NCT00410865
Wild Type p53 Adenovirus for Oral Premalignancies
Phase 1
Terminated
4 enrolled
M.D. Anderson Cancer Center
Department of Health and Human Services · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Primary Objectives: 1. To determine the maximum tolerated dose and transduction efficiency of adenoviral mediated wild type p53 gene transfer in premalignancies of the upper aerodigestive tract. 2. To determine the efficacy of single agent adenoviral mediated wild type p53 gene transfer in reversing oral premalignancies.
Timeline
- Start
- 2003-06
- Primary completion
- 2008-03
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CONTUSUGENE LADENOVEC | Unknown | — | Other |